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been recognised that high glucose concentration can also affect the activities of the matrix metalloproteinases (MMPs), a large group of metal ion-dependent enzymes responsible for matrix degradation. Studies from our own laboratory and by others have shown that the high glucose concentration in diabetes can alter the activities of these enzymes in mesangial cells and in isolated glomeruli [3±5] .
While initially believed to have a solely haemodynamic basis, the renoprotective effects of angiotensin converting enzyme (ACE) inhibition could also include reduction in the non-haemodynamic effects of angiotensin II [6] . In vivo studies have shown that ACE inhibition attenuates the increased synthesis of ECM in diabetes [7, 8] . However, the effects of ACE therapy on matrix degradative pathways have not been examined in detail in the in vivo setting. Most investigations in both human and experimental diabetes have focussed on the changes in ECM deposition within the glomerulus. But a number of studies have also shown a concomitant accumulation of the matrix within the tubulointerstitium [1, 9, 10] . Indeed, the deposition of ECM within the tubulointerstitium also correlates closely with the progression of renal disease in diabetes. This study examined the effects of ACE inhibition on the degradative pathways of the major renal ECM protein, type IV collagen [11] , in the whole kidney of animals with experimental diabetes.
Materials and methods
Animals. Diabetes was induced in 16 Sprague Dawley rats by the intravenous injection of streptozocin (50 mg/kg). A further eight age-matched rats, injected with citrate buffer, were used as non-diabetic controls. All diabetic rats received 4 U/day long-acting insulin (Ultratard, Novo-Nordisk, Bagsvegaard, Sweden) to maintain body weight and to prevent ketoacidosis. To determine the effect of ACE inhibition, diabetic rats were also allocated at random to receive the ACE inhibitor perindopril (n = 8, Servier, Neuilly, France) in their drinking water (2 mg/l). This was equivalent to a mean dose of (2 mg/kg/day) for the duration of the study. Both courses of treatment commenced 1 week after the induction of diabetes.
Seven days before the rats were killed, they were housed in metabolic cages for 24 h to obtain urine for the measurement of albumin by radioimmunoassay [12] . At 24 weeks of diabetes, rats were anaesthetised with pentobarbital and the kidneys obtained for RNA extraction and immunohistochemistry as previously described [13] . Blood obtained at death was collected in lithium heparin tubes, spun, separated and stored at ±20 C. The HbA 1 c was determined by high performance liquid chromatography. All aspects of the experiment were approved by the Animal Ethics Committee of the Austin and Repatriation Medical Centre, Melbourne, Australia.
MMP and TIMP gene expression. Kidney tissue was homogenised (Ultra-Turrax, Janke and Kunkel, Stafen, Germany) and total RNA isolated using the guanidinium isothiocyanate-phenol-chloroform extraction method [14] . One microgram aliquots of kidney tissue from each rat were reverse transcribed into cDNA using oligo dT (10pmol, Gibco-BRL, Sydney Australia) and Superscript II RNase H ± (Gibco-BRL) according to the manufacturers instructions. The gelatinases MMP-2 and MMP-9, and the tissue inhibitors of MMPs, TIMP-1 and TIMP-2 were amplified using 2U Taq polymerase (P. E. Biosystems, Forster City, Calif., USA) and 20 pmol of each forward and reverse primer as shown in Table 1 . The cycling parameters were denaturation (94 C, 15 s), annealing (54 C, 30 s) and extension (72 C, 30 s) [15] . The number of cycles (25±30) for each MMP or TIMP was selected to be well within the linear amplification range. Gene expression of beta actin was also measured in each sample and used as control for loading and reverse transcription efficiency. Negative control RT-PCR reactions was done by omitting either the reverse transcriptase enzyme or the RNA from the reaction mixture. All negative controls failed to produce PCR amplicons (data not shown). The resulting PCR products were electrophoretically fractionated on polyacrylamide gels (12.5 %) and visualised by staining with SYBR Green II (Molecular Probes, Eugene, OR, USA). Gels were then photographed and the images directly digitised using GrabIt software (UVP, Cambridge, UK) the intensity of the bands was determined using the Phoretix Image Analysis Programme (Phoretix International, Newcastle Upon Tyne, UK). Results were expressed as a ratio of band intensity corrected for abundance of the housekeeping gene, beta-actin.
Gelatinase activity. Tissue samples (100 mg) were homogenised and the protein concentration determined (Biorad DC, Sigma, Australia). The protein concentration in each sample was standardised and the presence of gelatinase activity determined by zymography as previously described [16] and according to the methodology of Zucker et al in which protein samples are assayed within the linear part of the calibration curve [17] . In brief, kidney samples (20 mg protein) from each experimental animal were mixed with sample buffer and loaded onto a 10 % SDS polyacrylamide gel containing 1 mg/ml gelatin and electrophoresed under non-reducing conditions (100 mA/gel). After electrophoresis the gels were washed in 50 mmol/l TRIS buffer, pH 7.6 containing 2.5 % Triton X-100 to displace SDS. The gels were incubated for a further 24 h in 50 mmol/l TRIS buffer containing 5 mmol/l CaCl 2 pH 7.6 and gelatin degrading enzymes were identified by staining with Coomassie Blue and destaining in methanol/acetic acid/H2O. Using this method, gelatinases appear as clear bands on a blue background and can be identified by their molecular weight. Gels were photographed and directly digitised using GrabIt software (UVP, Cambridge, UK) band size was determined using the Phoretix Image Analysis Program (Phoretix International, Newcastle -Upon-Tyne, UK). Ability of kidney tissue to degrade matrix and preparation of labelled matrix substrate. Labelled mesangium matrix substrate was prepared for use in the degradation studies as previously described [3] . Briefly, mesangial cells were plated in 12-well plates and cultured in RPMI (Gibco-BRL, Sydney, Australia) medium containing 10 % FCS. At approximately 60 % confluence the medium was changed to RPMI containing 10 % FCS and [ 35 S] methionine (Tran 35 S label; ICN, Irvine, Calif., USA). At confluence the media was removed and the mesangial cells washed with phosphate buffered saline (PBS) and separated from their matrix with 0.25 N NH 4 OH at 37 C for 30 min. The labelled matrices were then washed with distilled water, fixed with 70 % ethanol and exposed to UV light for 10 min. Just before the degradation studies, the matrices were again washed with PBS.
Degradation studies. Labelled matrices prepared as described above were used to study the effect of ACE inhibition on the activities of proteolytic enzymes in the kidney tissue. For these studies, duplicates of samples from experimental animal containing 20 mg protein were resuspended in 500 ml of 50 mmol/ l TRIS buffer containing 5 mmol/l CaCl 2 and incubated with the labelled matrix substrate for 24 h at 37 C. The degradative ability of each sample was also determined after inhibition with EDTA or activation of enzymes with aminophenylmercuric acetate (APMA). Activation was achieved by incubation of the kidney tissue with 1 mmol/l APMA for 1 h at 37 C before incubation with the labelled matrix substrate. Degradation was then assessed by counting the release of [ 35 S] methionine from the substrate in a liquid scintillation counter (2500TR, Packard Instruments City, Conn., USA) and expressed as disintegrations per minute (DPM).
The non-specific release of radioactivity was determined by incubation of the matrices in the presence of 50 mmol/l TRIS buffer (containing 5 mmol/l CaCl 2 ) and 0.1 % albumin and was found to be 5.4 2.3 % of the total count. Control experiments, co-incubating the kidney tissue with EDTA or 1,10 phenanthroline (10 mmol/l final concentration) before measuring the degradative activity, inhibited the ability of the tissue to degrade the matrix by 75.6 5.6 %. This decrease indicated that most of the degradation was due to the actions of MMPs.
Type IV collagen accumulation. Type IV collagen accumulation was assessed immunohistochemically as previously described [11] . Briefly, sections (4mm) of the formalin fixed and paraffin embedded kidney were placed onto slides, deparaffinised and rehydrated. To retrieve antigenicity from formalin fixation, sections were incubated for 10 min in 10 mmol/l sodium citrate buffer using a microwave oven. Endogenous peroxidase activity was blocked by further pretreatment with 1 % H 2 O 2 / methanol followed by incubation in protein blocking agent (Lipshaw-Immunon, Pittsburgh, Penn., USA) for 20 min at room temperature. The sections were then incubated with polyclonal goat anti-bovine/anti human type IV collagen antibody (Southern Biotechnology, Birmingham, Alabama, USA) overnight at 4 C. The following day the sections were thoroughly washed in PBS and incubated with rabbit anti-goat (1:200) biotinylated IgG (DAKO, Carpinteria Calif., USA) followed by avidin-biotin peroxidase complex (Vector, Burlingame, Calif., USA). Localisation of the peroxidase conjugates was achieved using diaminobenizidine tetrahydrochloride as a chromagen. Sections incubated in the absence of either primary antibody or in the presence of normal rabbit IgG served as negative controls.
The amount of Type IV collagen accumulation was assessed by examining immunostained sections using the computer-assisted image analysis method [18±20]. In brief, the colour range for positive brown staining on immunoperoxidase labelled sections was selected and image analysis done using a chromogen-sensitive technique [18] . Images from three non-overlapping, randomly selected fields of each experimental animal were examined using light microscopy (Olympus BX-50, Olympus Optical, Tokyo, Japan) and digitised using a high-resolution camera (Fujix HC-2000, Fujifilm, Tokyo, Japan). The proportional area occupied by immunoreactive type IV collagen was then calculated. All images were obtained using a 20 objective lens. Digitised images were then captured on a Power Macintosh G3 computer (Apple Computer, Cupertino, Calif., USA) and evaluated using analytical software (AIS, Analytical Imaging Software, City Ontario, Canada).
Statistical analysis. Because of a positively skewed distribution, AER was logarithmically transformed before statistical analysis and expressed as the geometric mean´/¸tolerance factor. Other results are expressed as means SEM unless stated otherwise. Data were compared using analysis of variance (ANO-VA) followed by post hoc comparison using Duncan's Multiple Range test. Analyses were done using the Statview SE + Graphics package (Abacus Concepts, Calabasas, Calif., USA) on an Apple Macintosh G3 (Apple Computer). A p value < 0.05 was considered statistically significant.
Results
Clinical parameters. All rats that received streptozocin became diabetic (blood glucose > 15 mmol/l) and treatment of diabetic rats with perindopril had no effect on blood glucose concentrations or HbA 1 c when compared with untreated diabetic animals ( Table 2) . Diabetes was associated with an increase (p < 0.01) in kidney weight and loss in body weight. These changes were also not affected by perindopril treatment. The AERs and systolic BP of the perindopril treated rats were similar to those observed in the control animals and significantly less than those seen in diabetic animals ( Table 2 ).
Gene expression of MMPs and TIMPs. Gene expression of MMP-2 was increased while MMP-9 mRNA was decreased in kidney tissue from diabetic animals when compared with non-diabetic controls (Fig. 1A  and 1B, respectively) . TIMP-1 gene expression was also increased in diabetic rat kidneys (Fig. 2) . These changes in expression of MMP-2, MMP-9 and TIMP-1 were all prevented by treatment with perindopril. TIMP-2 gene expression did not differ among any of the experimental groups (data not shown).
Gelatinase activity. Gelatin zymography (Fig. 3A) revealed two major bands of enzymatic activity in kidney extracts, corresponding to MMP-9 (92 kDa) and MMP-2 (72 kDa). Diabetes was associated with a reduction in both MMP-2 and MMP-9, a decrease prevented by treatment of diabetic animals with perindopril ( Fig. 3B and 3C) .
Matrix degradative activity. Total matrix degradative activity as assessed by release of [
35 S] methionine from the radiolabelled matrix substrate was reduced in kidney homogenates from diabetic rats compared with control rats. This decrease in degradative activity was normalised by perindopril treatment (Fig. 4A) . Addition of APMA to the kidney homogenates increased the degradative activity two-to threefold in all samples irrespective of treatment such that matrix degradation remained impaired in APMA-treated tissue samples from diabetic rats (Fig. 4B) .
Type IV collagen. Immunohistochemistry showed an increase in Type IV collagen in the kidney sections obtained from diabetic rats compared with control and perindopril-treated diabetic rats (Table 3 ). Increased immunostainable type IV collagen was present both in glomeruli (Fig. 5 ) and in the tubulointerstitium (Fig. 6 ) of diabetic rat kidneys.
Discussion
This study uncovers several findings in relation to the pathogenesis of experimental diabetes. Firstly, impaired degradation contributes to ECM accumulation in the diabetic kidney. Secondly, the beneficial effects of ACE inhibition on matrix accumulation could, in part, be mediated by its effects on the activities of enzymes involved in matrix degradation. Thirdly, in the diabetic context, changes in enzyme activity cannot be inferred from alterations in gene expression alone.
The pathological hallmark of progressive renal disease is the accumulation of ECM in the glomerulus and tubulointerstitium with changes at both sites correlating closely with declining renal function (reviewed in [21] ). This accumulation results from an imbalance between synthetic and degradative pathways. While the mechanisms mediating increased synthesis have been the focus of considerable attention, changes in the matrix degradative pathway in progressive kidney disease have not been explored in detail. Matrix degradation is largely mediated by the MMPs, a family of some 26 zinc-dependent enzymes that are active at neutral pH and secreted extracellularly as inactive zymogens [22] . Their activities are tightly regulated at multiple levels; by modulation in transcription, by changes in the rate of posttranslational modification via enzyme-dependent cleavage of pro-MMPs and by alterations in the concentration of specific inhibitors, the TIMPs. In this study, degradation of type IV collagen, the major ECM component of both the glomerulus and tubulointerstitium [11] increased at both sites in experimental [7, 8] and human diabetes [23] . Gene expression of the type IV collagenases, MMP-2 and MMP-9 were affected in different ways by the diabetic state, with increased gene expression of MMP-2 and reduced expression of MMP-9. The differential regulation of the components of the matrix degradative pathways has been previously documented [24, 25] and could be influenced by a range of factors which are altered in the diabetic milieu [26] . In particular, transforming growth factor-b (TGF-b), a prosclerotic growth factor, that has been consistently implicated in the ECM accumulation of diabetic nephropathy [27] acts by inhibiting matrix degradation as well as by stimulating its synthesis [28] . Indeed, our findings that MMP-2 and TIMP-1 gene expression were increased, while MMP-9 mRNA was decreased, were consistent with the described actions of TGF-b [25, 26] . Furthermore, perindopril altered the changes in MMP-2 and TIMP-1 consistent with a previously reported diminution in the overexpression of TGF-b with ACE inhibition [7] . Previous in vivo studies have examined only the gene expression [4, 29, 30] . Furthermore, these studies have focussed on MMP-1 and MMP-3, enzymes which degrade type I collagen and matrix glycoproteins and not collagen IV, the major ECM component of both the glomerulus and tubulointerstitium in the diabetic kidney [7, 29] . This study has not only examined gene expression of the major components of the type IV collagen degradative pathway, but has also assessed the activities of these enzymes. In this study, despite the increase in MMP-2 mRNA, enzyme activity of both MMP-2 and MMP-9 as assessed by zymogram was impaired in tissue from diabetic rat kidneys. This decrease in activity by zymography is most likely to be due to a decrease in enzyme mass and cannot be explained by the overexpression of TIMP-1 as the high SDS concentration separates TIMPs from MMPs during zymography.
In addition to the specific changes in the type IV collagen degradative pathway, we also noted a net decrease in the ability of kidney tissue from diabetic rats to degrade a radiolabelled matrix substrate. The presence of MMPs in the kidney tissue was confirmed by the inhibition of the majority of their activity with EDTA or 1:10 phenanthroline [16] . Furthermore, when non-proteolytic activation of all MMPs was induced by the addition of the organomercurial, APMA, to the tissue sample, there was a two-fold increase in matrix degrading capacity of kidney tissue. However, APMA treatment did not abolish the difference between kidney tissue from diabetic and control rats. These findings indicate that in addition to changes in TIMPs, diabetes was associated with an overall decrease in the total MMP mass. Several studies in both humans [31±33] and experimental rats [34, 35] have shown a renoprotective ef-A B Fig. 4 (A, B) . Degradation of a labelled matrix substrate by kidney tissue from control (C) diabetic (D) and perindopriltreated diabetic rats (D + Per) either before (A) or after (B) activation of matrix metalloproteinases with APMA. *p < 0.05 significantly different from control V Fig. 5 (A±C) . Representative photomicrographs of glomeruli from control (A), diabetic (B) and perindopril-treated diabetic rats (C) immunostained with antibody to type IV collagen. Increased immunostainable type IV collagen (brown) is present in the glomeruli of diabetic rat kidneys compared with controls and perindopril treated diabetic animals. Magnification 320 fect of ACE inhibition in diabetes. In vitro, angiotensin II, the effector molecule of the renin-angiotensin system, stimulates TGF-b expression in mesangial cells [36] , proximal tubular epithelial cells [37] and renal interstitial fibroblasts [38] . Furthermore, in experimental diabetes, blockade of the renin-angiotensin system leads not only to a reduction in glomerular ultrastructural damage [39] and reduced ECM gene transcription in the glomerulus [8] , but also to a reduction in both TGF-b and collagen accumulation in the tubulointerstitium [7] . Similar effects of ACE inhibition on ECM accumulation have also been recently reported in human diabetic nephropathy [40] . Whether these beneficial changes are due to modulation of degradative as well as synthetic pathways is not clear [7, 8] . In contrast to our study, Nakamura et al did not demonstrate an effect of enalapril on MMP or TIMP gene expression. The reason for differences are not clear but could reflect the MMPs examined and ACE inhibitor used. The findings of our study are, however, most consistent with the previously reported in vitro experiments in which exposure of cultured mesangial cells to high glucose decreased MMP-2 activity by an angiotensin II-dependent pathway [41] . Together with the results of this study, these findings indicate the important interactions between hyperglycaemia and the renin-angiotensin system in mediating ECM accumulation in diabetes by both impairing its degradation as well as increasing its synthesis. Preventing these effects could contribute to the beneficial effects of ACE inhibition on the structural as well as the functional abnormalities of diabetic nephropathy. 
